Latest News and Press Releases

EMERYVILLE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...

EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...

Second quarter 2020 HEPLISAV-B® net product revenue of $2.4 millionMultiple new CpG 1018 collaborations established to develop novel adjuvanted vaccine candidates across several indications, including...

SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotideTriSalus plans to further develop SD-101 as an oncology therapeutic ...

EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will...

Collaboration focused on developing an adjuvanted COVID-19 vaccine using Medigen’s subunit vaccine candidate with Dynavax’s CpG 1018In preclinical testing, the combination generated strong virus...

Ms. Julie Eastland, a strategic and financial executive with over 25 years of experience in biotechnology companiesMr. Brent MacGregor, a senior executive with over 20 years of global strategy and...

Development funded under contract award from NIAID/NIH as part of the CIVICs programCurrently no approved universal influenza vaccineCDC estimates 35.5 million people were infected with influenza in...

Medicago expects to enroll 180 healthy adult participantsPreliminary safety and immunogenicity results are expected in October 2020Dynavax is providing CpG 1018, the adjuvant contained in its U.S....

-   People with diabetes are two times more likely to become infected with the hepatitis B virus (HBV) and up to four times as likely to get HBV-related liver cancer -   Hawaii has one of the highest...